Therapeutic effect of metformin in the treatment of endometrial cancer (Review)
- Authors:
- Nan Mu
- Tingting Xu
- Mingxiao Gao
- Mei Dong
- Qing Tang
- Li Hao
- Guiqing Wang
- Zenghui Li
- Wenshuang Wang
- Ying Yang
- Jianqing Hou
-
Affiliations: Department of Gynecology and Obstetrics, Yantai Yuhuangding Hospital Affiliated to Qingdao University, Yantai, Shandong 264000, P.R. China, Department of Cardiology, Yantai Yuhuangding Hospital Affiliated to Qingdao University, Yantai, Shandong 264000, P.R. China - Published online on: August 24, 2020 https://doi.org/10.3892/ol.2020.12017
- Article Number: 156
This article is mentioned in:
Abstract
 |
 |
|
Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
van Weelden WJ, Massuger LFAG, ENITE C, Pijnenborg JMA and Romano A: Anti-estrogen treatment in endometrial cancer: A systematic review. Front Oncol. 9:3592019. View Article : Google Scholar : PubMed/NCBI | |
|
Mu N, Zhu Y, Wang Y, Zhang H and Xue F: Insulin resistance: A significant risk factor of endometrial cancer. Gynecol Oncol. 125:751–757. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Shao Y, Cheng S, Hou J, Zuo Y, Zheng W, Xia M and Mu N: Insulin is an important risk factor of endometrial cancer among premenopausal women: A case-control study in China. Tumour Biol. 37:4721–4726. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Arthur RS, Kabat GC, Kim MY, Wild RA, Shadyab AH, Wactawski-Wende J, Ho GYF, Reeves KW, Kuller LH, Luo J, et al: Metabolic syndrome and risk of endometrial cancer in postmenopausal women: A prospective study. Cancer Causes Control. 30:355–363. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Mu N, Dong M, Liu C, Wang X, Cong J, Wang L, Wang X, Lakhani I, Liu X, Hou J, et al: Association between preoperative serum insulin levels and lymph node metastasis in endometrial cancer-a prospective cohort study. Cancer Med. 7:1519–1527. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E and Vergote I: Endometrial cancer. Lancet. 366:491–505. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Carneiro MM, Lamaita RM, Ferreira MC and Silva-Filho AL: Fertility-preservation in endometrial cancer: Is it safe? Review of the literature. JBRA Assist Reprod. 20:232–239. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Koopman E, Blok LJ, Brinkmann AO, Helmerhorst TJ and Huikeshoven FJ: Differential gene expression in progesterone-sensitive and progesterone-insensitive endometrial carcinoma cells. Eur J Obstet Gynecol Reprod Biol. 82:135–138. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Marjoribanks J, Farquhar C, Roberts H, Lethaby A and Lee J: Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 1:CD0041432017.PubMed/NCBI | |
|
Mallik R and Chowdhury TA: Metformin in cancer. Diabetes Res Clin Pract. 143:409–419. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Gadducci A, Biglia N, Tana R, Cosio S and Gallo M: Metformin use and gynecological cancers: A novel treatment option emerging from drug repositioning. Crit Rev Oncol Hematol. 105:73–83. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Yamana H, Kato K, Kobara H, Fujihara S, Fujita K, Namima D, Fujita N, Kobayashi K, Kamada H, Morishita A, et al: Metformin inhibits proliferation and tumor growth of QGP-1 pancreatic neuroendocrine tumor cells by inducing cell cycle arrest and apoptosis. Anticancer Res. 40:121–132. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Klubo-Gwiezdzinska J, Jensen K, Costello J, Patel A, Hoperia V, Bauer A, Burman KD, Wartofsky L and Vasko V: Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells. Endocr Relat Cancer. 19:447–456. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Liu S, Yue C, Chen H, Chen Y and Li G: Metformin promotes Beclin1-Dependent autophagy to inhibit the progression of gastric cancer. Onco Targets Ther. 13:4445–4455. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Ye J, Qi L, Chen K, Li R, Song S, Zhou C and Zhai W: Metformin induces TPC-1 cell apoptosis through endoplasmic reticulum stress-associated pathways in vitro and in vivo. Int J Oncol. 55:331–339. 2019.PubMed/NCBI | |
|
Mu N, Dong M, Li L, Xia M, Qv L, Wang Y, Dong C, Chen Y, Zuo Y, Hou J and Xue F: Synergistic effect of metformin and medroxyprogesterone 17acetate on the development of endometrial cancer. Oncol Rep. 39:2015–2021. 2018.PubMed/NCBI | |
|
Hari Kumar KVS: The good, the bad, and the ugly facets of insulin resistance. Med J Armed Forces India. 76:4–7. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Luc K, Schramm-Luc A, Guzik TJ and Mikolajczyk TP: Oxidative stress and inflammatory markers in prediabetes and diabetes. J Physiol Pharmacol. 70:809–824. 2019. | |
|
Patel TP, Rawal K, Bagchi AK, Akolkar G, Bernardes N, Dias DDS, Gupta S and Singal PK: Insulin resistance: An additional risk factor in the pathogenesis of cardiovascular disease in type 2 diabetes. Heart Fail Rev. 21:11–23. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Yang C, Qu H, Zhao X, Hu Y, Xiong J, Jiang X, Chen Y and Li Z: Plasma secretagogin is increased in individuals with glucose dysregulation. Exp Clin Endocrinol Diabetes. Sep 23–2019.(Epub ahead of print). doi: 10.1055/a-1001-2244. | |
|
Kheirandish M, Mahboobi H, Yazdanparast M, Kamal W and Kamal MA: Anti-cancer effects of metformin: Recent evidences for its role in prevention and treatment of cancer. Curr Drug Metab. 19:793–797. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Pollak M: The insulin and insulin-like growth factor receptor family in neoplasia: An update. Nat Rev Cancer. 12:159–169. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Eritja N, Mirantes C, Llobet D, Yeramian A, Bergadà L, Dosil MA, Domingo M, Matias-Guiu X and Dolcet X: Long-term estradiol exposure is a direct mitogen for insulin/EGF-primed endometrial cells and drives PTEN loss-induced hyperplasic growth. Am J Pathol. 183:277–287. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Arcidiacono B, Iiritano S, Nocera A, Possidente K, Nevolo MT, Ventura V, Foti D, Chiefari E and Brunetti A: Insulin resistance and cancer risk: An overview of the pathogenetic mechanisms. Exp Diabetes Res. 2012:7891742012. View Article : Google Scholar : PubMed/NCBI | |
|
Kliemann N, Murphy N, Viallon V, Freisling H, Tsilidis KK, Rinaldi S, Mancini FR, Fagherazzi G, Boutron-Ruault MC, Boeing H, et al: Predicted basal metabolic rate and cancer risk in the European prospective investigation into cancer and nutrition. Int J Cancer. 147:648–661. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Bjorge T, Haggstrom C, Ghaderi S, Nagel G, Manjer J, Tretli S, Ulmer H, Harlid S, Rosendahl AH, Lang A, et al: BMI and weight changes and risk of obesity-related cancers: A pooled European cohort study. Int J Epidemiol. 48:1872–1885. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Lai Y and Sun C: Association of abnormal glucose metabolism and insulin resistance in patients with atypical and typical endometrial cancer. Oncol Lett. 15:2173–2178. 2018.PubMed/NCBI | |
|
Xu WH, Matthews CE, Xiang YB, Zheng W, Ruan ZX, Cheng JR, Gao YT and Shu XO: Effect of adiposity and fat distribution on endometrial cancer risk in Shanghai women. Am J Epidemiol. 161:939–947. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Yoon YS, Kwon AR, Lee YK and Oh SW: Circulating adipokines and risk of obesity related cancers: A systematic review and meta-analysis. Obes Res Clin Pract. 13:329–339. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Che Q, Xiao X, Liu M, Lu Y, Dong X and Liu S: IL-6 promotes endometrial cancer cells invasion and migration through signal transducers and activators of transcription 3 signaling pathway. Pathol Res Pract. 215:1523922019. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Hua S, Tian W, Zhang L, Zhao J, Zhang H, Zhang W and Xue F: Mitogenic and anti-apoptotic effects of insulin in endometrial cancer are phosphatidylinositol 3-kinase/Akt dependent. Gynecol Oncol. 125:734–741. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Manson JE, Li J, Harris TG, Rohan TE, Xue X, Ho GY, et al: A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev. 17:921–929. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Anastasi E, Filardi T, Tartaglione S, Lenzi A, Angeloni A and Morano S: Linking type 2 diabetes and gynecological cancer: An introductory overview. Clin Chem Lab Med. 56:1413–1425. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Yang X and Wang J: The role of metabolic syndrome in endometrial cancer: A review. Front Oncol. 9:7442019. View Article : Google Scholar : PubMed/NCBI | |
|
MacKintosh ML, Derbyshire AE, McVey RJ, Bolton J, Nickkho-Amiry M, Higgins CL, Kamieniorz M, Pemberton PW, Kirmani BH, Ahmed B, et al: The impact of obesity and bariatric surgery on circulating and tissue biomarkers of endometrial cancer risk. Int J Cancer. 144:641–650. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Mitsuhashi A, Kiyokawa T, Sato Y and Shozu M: Effects of metformin on endometrial cancer cell growth in vivo: A preoperative prospective trial. Cancer. 120:2986–2995. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang K, Luo Y, Dai H and Deng Z: Effects of bariatric surgery on cancer risk: Evidence from meta-analysis. Obes Surg. 30:1265–1272. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Soliman PT, Zhang Q, Broaddus RR, Westin SN, Iglesias D, Munsell MF, Schmandt R, Yates M, Ramondetta L and Lu KH: Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer: A window of opportunity study. Gynecol Oncol. 143:466–471. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Yates MS, Coletta AM, Zhang Q, Schmandt RE, Medepalli M, Nebgen D, Soletsky B, Milbourne A, Levy E, Fellman B, et al: Prospective randomized biomarker study of metformin and lifestyle intervention for prevention in obese women at increased risk for endometrial cancer. Cancer Prev Res (Phila). 11:477–490. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, et al: Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 108:1167–1174. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Vallianou NG, Evangelopoulos A and Kazazis C: Metformin and cancer. Rev Diabet Stud. 10:228–235. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, An H, Liu T, Qin C, Sesaki H, Guo S, Radovick S, Hussain M, Maheshwari A, Wondisford FE, et al: Metformin improves mitochondrial respiratory activity through activation of AMPK. Cell Rep. 29:1511–1523 e5. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang S, Wang Y, Luo L, Shi F, Zou J, Lin H, Ying Y, Luo Y, Zhan Z, Liu P, et al: AMP-activated protein kinase regulates cancer cell growth and metabolism via nuclear and mitochondria events. J Cell Mol Med. 23:3951–3961. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Pena CG, Nakada Y, Saatcioglu HD, Aloisio GM, Cuevas I, Zhang S, Miller DS, Lea JS, Wong KK, DeBerardinis RJ, et al: LKB1 loss promotes endometrial cancer progression via CCL2-dependent macrophage recruitment. J Clin Invest. 125:4063–4076. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Saraei P, Asadi I, Kakar MA and Moradi-Kor N: The beneficial effects of metformin on cancer prevention and therapy: A comprehensive review of recent advances. Cancer Manag Res. 11:3295–3313. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
El-Sisi AE, Sokar SS, El-Sayad ME, Moussa EA and Salim EI: Anticancer effect of metformin against 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine-induced rat mammary carcinogenesis is through AMPK pathway and modulation of oxidative stress markers. Hum Exp Toxicol. 38:703–712. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Cantrell LA, Zhou C, Mendivil A, Malloy KM, Gehrig PA and Bae-Jump VL: Metformin is a potent inhibitor of endometrial cancer cell proliferation-implications for a novel treatment strategy. Gynecol Oncol. 116:92–98. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Pabona JMP, Burnett AF, Brown DM, Quick CM, Simmen FA, Montales MTE, Liu SJ, Rose T, Alhallak I, Siegel ER and Simmen RC: Metformin promotes anti-tumor biomarkers in human endometrial cancer cells. Reprod Sci. 27:267–277. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Iglesias DA, Yates MS, van der Hoeven D, Rodkey TL, Zhang Q, Co NN, Burzawa J, Chigurupati S, Celestino J, Bowser J, et al: Another surprise from Metformin: Novel mechanism of action via K-Ras influences endometrial cancer response to therapy. Mol Cancer Ther. 12:2847–2856. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Guo H, Kong W, Zhang L, Han J, Clark LH, Yin Y, Fang Z, Sun W, Wang J, Gilliam TP, et al: Reversal of obesity-driven aggressiveness of endometrial cancer by metformin. Am J Cancer Res. 9:2170–2193. 2019.PubMed/NCBI | |
|
Moroi AJ and Watson SP: Impact of the PI3-kinase/Akt pathway on ITAM and hemITAM receptors: Haemostasis, platelet activation and antithrombotic therapy. Biochem Pharmacol. 94:186–194. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Martini M, De Santis MC, Braccini L, Gulluni F and Hirsch E: PI3K/AKT signaling pathway and cancer: An updated review. Ann Med. 46:372–383. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Guo S, Loibl S, von Minckwitz G, Darb-Esfahani S, Lederer B and Denkert C: PIK3CA H1047R mutation associated with a lower pathological complete response rate in triple-negative breast cancer patients treated with anthracycline-taxane-based neoadjuvant chemotherapy. Cancer Res Treat. 52:689–696. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Jhanwar-Uniyal M, Wainwright JV, Mohan AL, Tobias ME, Murali R, Gandhi CD and Schmidt MH: Diverse signaling mechanisms of mTOR complexes: mTORC1 and mTORC2 in forming a formidable relationship. Adv Biol Regul. 72:51–62. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Johnston SB and Raines RT: Catalysis by the tumor-suppressor enzymes PTEN and PTEN-L. PLoS One. 10:e01168982015. View Article : Google Scholar : PubMed/NCBI | |
|
Kim SM, Nguyen TT, Ravi A, Kubiniok P, Finicle BT, Jayashankar V, Malacrida L, Hou J, Robertson J, Gao D, et al: PTEN Deficiency and AMPK activation promote nutrient scavenging and anabolism in prostate cancer cells. Cancer Discov. 8:866–883. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Leitner MG, Hobiger K, Mavrantoni A, Feuer A, Oberwinkler J, Oliver D and Halaszovich CR: A126 in the active site and TI167/168 in the TI loop are essential determinants of the substrate specificity of PTEN. Cell Mol Life Sci. 75:4235–4250. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Salvesen HB, Werner HM and Krakstad C: PI3K pathway in gynecologic malignancies. Am Soc Clin Oncol Educ Book. Jun 31–2013.(Epub ahead of print). doi: 10.1200/EdBook_AM.2013.33.e218. View Article : Google Scholar : PubMed/NCBI | |
|
Mackay HJ, Eisenhauer EA, Kamel-Reid S, Tsao M, Clarke B, Karakasis K, Werner HM, Trovik J, Akslen LA, Salvesen HB, et al: Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer. Cancer. 120:603–610. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
de Melo AC, Paulino E and Garces AH: A review of mTOR pathway inhibitors in gynecologic cancer. Oxid Med Cell Longev. 2017:48097512017. View Article : Google Scholar : PubMed/NCBI | |
|
Kosmas K, Mitropoulou G, Provatas I, Stamoulas M and Marouga A: Expression of phosphatase and tensin homologue in imprint smears of endometrial carcinoma. Cytopathology. 29:558–564. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Roncolato F, Lindemann K, Willson ML, Martyn J and Mileshkin L: PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer. Cochrane Database Syst Rev. 10:CD0121602019.PubMed/NCBI | |
|
Saini N and Yang X: Metformin as an anti-cancer agent: Actions and mechanisms targeting cancer stem cells. Acta Biochim Biophys Sin (Shanghai). 50:133–143. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Qiang P, Shao Y, Sun YP, Zhang J and Chen LJ: Metformin inhibits proliferation and migration of endometrial cancer cells through regulating PI3K/AKT/MDM2 pathway. Eur Rev Med Pharmacol Sci. 23:1778–1785. 2019.PubMed/NCBI | |
|
Kasprzak A, Kwasniewski W, Adamek A and Gozdzicka-Jozefiak A: Insulin-like growth factor (IGF) axis in cancerogenesis. Mutat Res Rev Mutat Res. 772:78–104. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Li MX, Wang H, Zeng Z and Li XM: Metformin down-regulates endometrial carcinoma cell secretion of IGF-1 and expression of IGF-1R. Asian Pac J Cancer Prev. 16:221–225. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Tandon M, Chen Z, Othman AH and Pratap J: Role of Runx2 in IGF-1Rβ/Akt- and AMPK/Erk-dependent growth, survival and sensitivity towards metformin in breast cancer bone metastasis. Oncogene. 35:4730–4740. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Chen G, Yuan C, Duan F, Liu Y, Zhang J, He Z, Huang H, He C and Wang H: IGF1/MAPK/ERK signaling pathway-mediated programming alterations of adrenal cortex cell proliferation by prenatal caffeine exposure in male offspring rats. Toxicol Appl Pharmacol. 341:64–76. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Wang CF, Zhang G, Zhao LJ, Qi WJ, Li XP, Wang JL and Wei LH: Overexpression of the insulin receptor isoform A promotes endometrial carcinoma cell growth. PLoS One. 8:e690012013. View Article : Google Scholar : PubMed/NCBI | |
|
Shehab MA, Biggar K, Singal SS, Nygard K, Shun-Cheng Li S, Jansson T and Gupta MB: Exposure of decidualized HIESC to low oxygen tension and leucine deprivation results in increased IGFBP-1 phosphorylation and reduced IGF-I bioactivity. Mol Cell Endocrinol. 452:1–14. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Xie Y, Wang JL, Ji M, Yuan ZF, Peng Z, Zhang Y, Wen JG and Shi HR: Regulation of insulin-like growth factor signaling by metformin in endometrial cancer cells. Oncol Lett. 8:1993–1999. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Du J, Shi HR, Ren F, Wang JL, Wu QH, Li X and Zhang RT: Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells. BMC Cancer. 17:8512017. View Article : Google Scholar : PubMed/NCBI | |
|
Cai D, Sun H, Qi Y, Zhao X, Feng M and Wu X: Insulin-Like growth factor 1/mammalian target of rapamycin and AMP-Activated protein kinase signaling involved in the effects of metformin in the human endometrial cancer. Int J Gynecol Cancer. 26:1667–1672. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Cao C, Zhou JY, Xie SW, Guo XJ, Li GT, Gong YJ, Yang WJ, Li Z, Zhong RH, Shao HH and Zhu Y: Metformin enhances nomegestrol acetate suppressing growth of endometrial cancer cells and may correlate to downregulating mTOR activity in vitro and in vivo. Int J Mol Sci. 20:33082019. View Article : Google Scholar | |
|
Xu HL, Xu WH, Cai Q, Feng M, Long J, Zheng W, Xiang YB and Shu XO: Polymorphisms and haplotypes in the caspase-3, caspase-7, and caspase-8 genes and risk for endometrial cancer: A population-based, case-control study in a Chinese population. Cancer Epidemiol Biomarkers Prev. 18:2114–2122. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
McComb S, Chan PK, Guinot A, Hartmannsdottir H, Jenni S, Dobay MP, Bourquin JP and Bornhauser BC: Efficient apoptosis requires feedback amplification of upstream apoptotic signals by effector caspase-3 or −7. Sci Adv. 5:eaau94332019. View Article : Google Scholar : PubMed/NCBI | |
|
Aral K, Aral CA and Kapila Y: The role of caspase-8, caspase-9, and apoptosis inducing factor in periodontal disease. J Periodontol. 90:288–294. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Jang JH, Song IH, Sung EG, Lee TJ and Kim JY: Metformin-induced apoptosis facilitates degradation of the cellular caspase 8 (FLICE)-like inhibitory protein through a caspase-dependent pathway in human renal cell carcinoma A498 cells. Oncol Lett. 16:2030–2038. 2018.PubMed/NCBI | |
|
Zhao Y, Luo Q, Mo J, Li J, Ye D, Ao Z, Chen L and Liu J: Metformin in combination with JS-K inhibits growth of renal cell carcinoma cells via reactive oxygen species activation and inducing DNA breaks. J Cancer. 11:3701–3712. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou X, Zhang P and Wang Q, Ji N, Xia S, Ding Y and Wang Q: Metformin ameliorates experimental diabetic periodontitis independently of mammalian target of rapamycin (mTOR) inhibition by reducing NIMA-related kinase 7 (Nek7) expression. J Periodontol. 90:1032–1042. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Guo Y, Yuan J, Yin S, Wang X, Shuai R and Kang J: MAP2K6-FP enhances the sensitiveness of paclitaxel for ovarian cancer via inducing autophagy. Int J Gynecol Cancer. 27:1082–1087. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Giatromanolaki A, Koukourakis MI, Koutsopoulos A, Chloropoulou P, Liberis V and Sivridis E: High Beclin 1 expression defines a poor prognosis in endometrial adenocarcinomas. Gynecol Oncol. 123:147–151. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Bermudez M, Aguilar-Medina M, Lizarraga-Verdugo E, Avendaño-Félix M, Silva-Benítez E, López-Camarillo C and Ramos-Payán R: LncRNAs as regulators of autophagy and drug resistance in colorectal cancer. Front Oncol. 9:10082019. View Article : Google Scholar : PubMed/NCBI | |
|
Ran X, Zhou P and Zhang K: Autophagy plays an important role in stemness mediation and the novel dual function of EIG121 in both autophagy and stemness regulation of endometrial carcinoma JEC cells. Int J Oncol. 51:644–656. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Tomic T, Botton T, Cerezo M, Robert G, Luciano F, Puissant A, Gounon P, Allegra M, Bertolotto C, Bereder JM, et al: Metformin inhibits melanoma development through autophagy and apoptosis mechanisms. Cell Death Dis. 2:e1992011. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang D, Xuan J, Zheng BB, Zhou YL, Lin Y, Wu YS, Zhou YF, Huang YX, Wang Q, Shen LY, et al: Metformin improves functional recovery after spinal cord injury via autophagy flux stimulation. Mol Neurobiol. 54:3327–3341. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Takahashi A, Kimura F, Yamanaka A, Takebayashi A, Kita N, Takahashi K and Murakami T: Metformin impairs growth of endometrial cancer cells via cell cycle arrest and concomitant autophagy and apoptosis. Cancer Cell Int. 14:532014. View Article : Google Scholar : PubMed/NCBI | |
|
Zou G, Bai J, Li D and Chen Y: Effect of metformin on the proliferation, apoptosis, invasion and autophagy of ovarian cancer cells. Exp Ther Med. 18:2086–2094. 2019.PubMed/NCBI | |
|
Tseng CH: Metformin and endometrial cancer risk in Chinese women with type 2 diabetes mellitus in Taiwan. Gynecol Oncol. 138:147–153. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Franchi M, Asciutto R, Nicotra F, Merlino L, La Vecchia C, Corrao G and Bosetti C: Metformin, other antidiabetic drugs, and endometrial cancer risk: A nested case-control study within Italian healthcare utilization databases. Eur J Cancer Prev. 26:225–231. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ko EM, Walter P, Jackson A, Clark L, Franasiak J, Bolac C, Havrilesky LJ, Secord AA, Moore DT, Gehrig PA and Bae-Jump V: Metformin is associated with improved survival in endometrial cancer. Gynecol Oncol. 132:438–442. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Rossi A, Garber CE, Ortiz M, Shankar V, Goldberg GL and Nevadunsky NS: Feasibility of a physical activity intervention for obese, socioculturally diverse endometrial cancer survivors. Gynecol Oncol. 142:304–310. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Clement NS, Oliver TR, Shiwani H, Sanner JR, Mulvaney CA and Atiomo W: Metformin for endometrial hyperplasia. Cochrane Database Syst Rev. 10:CD0122142017.PubMed/NCBI | |
|
Mitsuhashi A, Sato Y, Kiyokawa T, Koshizaka M, Hanaoka H and Shozu M: Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer. Ann Oncol. 27:262–266. 2016. View Article : Google Scholar : PubMed/NCBI |
